Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;7(7):1217-29.
doi: 10.1002/cmdc.201200079. Epub 2012 May 3.

Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication

Affiliations

Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication

Akbar Ali et al. ChemMedChem. 2012 Jul.

Abstract

The human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) protein, essential for in vivo viral replication, protects the virus from innate antiviral cellular factor apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G; A3G) and is an attractive target for the development of novel antiviral therapeutics. We have evaluated the structure-activity relationships of N-(2-methoxyphenyl)-2-((4-nitrophenyl)thio)benzamide (RN-18), a small molecule recently identified as an inhibitor of Vif function that blocks viral replication only in nonpermissive cells expressing A3G, by inhibiting Vif-A3G interactions. Microwave-assisted cross-coupling reactions were developed to prepare a series of RN18 analogues with diverse linkages and substitutions on the phenyl rings. A dual cell-based assay system was used to assess antiviral activity against wild-type HIV-1 in both nonpermissive (H9) and permissive (MT4) cells that also allowed evaluation of specificity. In general, variations of phenyl substitutions were detrimental to antiviral potency and specificity, but isosteric replacements of amide and ether linkages were relatively well tolerated. These structure-activity relationship data define structural requirements for Vif-specific activity, identify new compounds with improved antiviral potency and specificity, and provide leads for further exploration to develop new antiviral therapeutics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical Structures of HIV-1 Vif Inhibitors RN18 and RN19.
Figure 2
Figure 2
a) A convergent route for the synthesis of RN18 and analogues; b) alternate route for the synthesis of RN18 and C-ring analogues.
Scheme 1
Scheme 1
Reagents and conditions: a) Cu(I)I, K2CO3, iPrOH, HOCH2CH2OH, MW (150 WT), 80 °C, 30 min (2 ×); b) SnCl2∙2H2O, EtOAc, 80 °C, 3 h.
Scheme 2
Scheme 2
Reagents and conditions: a) Cu(I)I, K2CO3, 1,2-DME, MW (150 WT), 80 °C, 30 min (2 ×); (b) Ba(OH)2∙8H2O, MeOH, 80 °C, 2 h; (c) (i) (COCl)2, CH2Cl2, DMF, RT, 8 h, (ii) R′R″NH (14a–h), Et3N, CH2Cl2, 0 °C to RT, overnight; d) SnCl2∙2H2O, EtOAc, 80 °C, 3 h.
Scheme 5
Scheme 5
Reagents and conditions: (a) Cu(I)Cl, Cs2CO3, CH2(Cot-Bu)2, NMP, MW (150 WT), 120 °C, 30 min (2 ×); b) Cu(OAc)2, CH2Cl2, PhOH, Et3N, 4A MS, RT, overnight; c) K2CO3, DMF, MW (150 WT), 90 °C, 30 min (2 ×).

References

    1. Joint United Nations Program on HIV/AIDS (UNAIDS) UNAIDS Report on the Global AIDS Epidemic 2010, UNAIDS. Geneva, Switzerland: 2010.
    1. Mehellou Y, De Clercq E. J. Med. Chem. 2010;53:521–538. - PubMed
    1. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. JAMA. 2010;304:321–333. - PubMed
    1. Volberding PA, Deeks SG. The Lancet. 2010;376:49–62. - PubMed
    1. Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F. Science. 1987;237:888–893. - PubMed

Publication types

MeSH terms

Substances